Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
BMC Cancer
    September 2017
  1. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    >> Share

  2. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    >> Share

  3. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    >> Share

  4. WENNERS A, Grambach J, Koss J, Maass N, et al
    Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    BMC Cancer. 2017;17:632.
    >> Share

  5. GOLDVASER H, Gal O, Rizel S, Hendler D, et al
    The association between smoking and breast cancer characteristics and outcome.
    BMC Cancer. 2017;17:624.
    >> Share

  6. HALLAMIES S, Pelttari LM, Poikonen-Saksela P, Jekunen A, et al
    CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
    BMC Cancer. 2017;17:620.
    >> Share

    August 2017
  7. KASHIWAGI S, Fukushima W, Asano Y, Goto W, et al
    Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    BMC Cancer. 2017;17:604.
    >> Share

  8. OBERGUGGENBERGER A, Martini C, Huber N, Fallowfield L, et al
    Self-reported sexual health: Breast cancer survivors compared to women from the general population - an observational study.
    BMC Cancer. 2017;17:599.
    >> Share

  9. YAMASHITA Y, Nishiumi S, Kono S, Takao S, et al
    Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.
    BMC Cancer. 2017;17:589.
    >> Share

  10. LIMA MTM, de Carvalho KP, Mazzutti FS, de Almeida Maia M, et al
    Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients.
    BMC Cancer. 2017;17:578.
    >> Share

  11. DUMA MN, Munch S, Oechsner M, Combs SE, et al
    Are heart toxicities in breast cancer patients important for radiation oncologists? A practice pattern survey in German speaking countries.
    BMC Cancer. 2017;17:563.
    >> Share

  12. CHEN K, Liu J, Li S, Jacobs L, et al
    Development of nomograms to predict axillary lymph node status in breast cancer patients.
    BMC Cancer. 2017;17:561.
    >> Share

  13. ANDERSEN ZJ, Jorgensen JT, Gron R, Brauner EV, et al
    Active smoking and risk of breast cancer in a Danish nurse cohort study.
    BMC Cancer. 2017;17:556.
    >> Share

  14. GAUCK D, Keil S, Niggemann B, Zanker KS, et al
    Hybrid clone cells derived from human breast epithelial cells and human breast cancer cells exhibit properties of cancer stem/initiating cells.
    BMC Cancer. 2017;17:515.
    >> Share

  15. WANG L, Widatalla SE, Whalen DS, Ochieng J, et al
    Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients.
    BMC Cancer. 2017;17:511.
    >> Share

    July 2017
  16. LUDOVINI V, Antognelli C, Rulli A, Foglietta J, et al
    Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
    BMC Cancer. 2017;17:502.
    >> Share

  17. DECKER T, Overkamp F, Rosel S, Nusch A, et al
    A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
    BMC Cancer. 2017;17:499.
    >> Share

  18. MAATTA KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, et al
    Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    BMC Cancer. 2017;17:496.
    >> Share

  19. WANG Q, Cheng Y, Wang Y, Fan Y, et al
    Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    BMC Cancer. 2017;17:492.
    >> Share

  20. YANES T, Meiser B, Young MA, Kaur R, et al
    Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.
    BMC Cancer. 2017;17:491.
    >> Share

  21. STEFANSSON OA, Hermanowicz S, van der Horst J, Hilmarsdottir H, et al
    CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.
    BMC Cancer. 2017;17:469.
    >> Share

  22. LANGIUS-EKLOF A, Crafoord MT, Christiansen M, Fjell M, et al
    Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cance
    BMC Cancer. 2017;17:466.
    >> Share

  23. VAN ROOZENDAAL LM, Vane MLG, van Dalen T, van der Hage JA, et al
    Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).
    BMC Cancer. 2017;17:459.
    >> Share

    June 2017
  24. GRINDEDAL EM, Heramb C, Karsrud I, Ariansen SL, et al
    Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    BMC Cancer. 2017;17:438.
    >> Share

  25. JACQUINOT Q, Meneveau N, Chatot M, Bonnetain F, et al
    A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    BMC Cancer. 2017;17:425.
    >> Share

  26. OZAKI A, Nomura S, Leppold C, Tsubokura M, et al
    Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.
    BMC Cancer. 2017;17:423.
    >> Share

  27. ZANOTTI G, Hunger M, Perkins JJ, Horblyuk R, et al
    Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
    BMC Cancer. 2017;17:393.
    >> Share

    May 2017
  28. YOO TK, Chang JM, Shin HC, Han W, et al
    An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment.
    BMC Cancer. 2017;17:389.
    >> Share

  29. DE BONIFACE J, Frisell J, Andersson Y, Bergkvist L, et al
    Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    BMC Cancer. 2017;17:379.
    >> Share

  30. WANG F, Tse LA, Chan WC, Kwok CC, et al
    Disparities of time trends and birth cohort effects on invasive breast cancer incidence in Shanghai and Hong Kong pre- and post-menopausal women.
    BMC Cancer. 2017;17:362.
    >> Share

  31. WILLIAMS V, Grosset AA, Zamorano Cuervo N, St-Pierre Y, et al
    Detection of IKKepsilon by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis.
    BMC Cancer. 2017;17:356.
    >> Share

  32. KUROZUMI S, Matsumoto H, Hayashi Y, Tozuka K, et al
    Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    BMC Cancer. 2017;17:354.
    >> Share

  33. LAMBERTINI M, Anserini P, Fontana V, Poggio F, et al
    The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients.
    BMC Cancer. 2017;17:346.
    >> Share

  34. ZHANG S, Zhang D, Gong M, Wen L, et al
    High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer.
    BMC Cancer. 2017;17:335.
    >> Share

  35. LAGENDIJK M, Vos EL, Koning AHJ, Hunink MGM, et al
    TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.
    BMC Cancer. 2017;17:336.
    >> Share

  36. DELGADO-GARCIA S, Martinez-Escoriza JC, Alba A, Martin-Bayon TA, et al
    Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study.
    BMC Cancer. 2017;17:320.
    >> Share

  37. VAN BOMMEL RMG, Weber R, Voogd AC, Nederend J, et al
    Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography.
    BMC Cancer. 2017;17:315.
    >> Share

  38. MARK KMK, Varn FS, Ung MH, Qian F, et al
    The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
    BMC Cancer. 2017;17:306.
    >> Share

  39. MU J, Zhu D, Shen Z, Ning S, et al
    The repressive effect of miR-148a on Wnt/beta-catenin signaling involved in Glabridin-induced anti-angiogenesis in human breast cancer cells.
    BMC Cancer. 2017;17:307.
    >> Share

    April 2017
  40. ZHU J, Ebert L, Liu X, Chan SW, et al
    A mobile application of breast cancer e-support program versus routine Care in the treatment of Chinese women with breast cancer undergoing chemotherapy: study protocol for a randomized controlled trial.
    BMC Cancer. 2017;17:291.
    >> Share

  41. SETYOWIBOWO H, Sijbrandij M, Iskandarsyah A, Hunfeld JAM, et al
    A protocol for a cluster-randomized controlled trial of a self-help psycho-education programme to reduce diagnosis delay in women with breast cancer symptoms in Indonesia.
    BMC Cancer. 2017;17:284.
    >> Share

  42. LABOVSKY V, Martinez LM, Davies KM, de Lujan Calcagno M, et al
    Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.
    BMC Cancer. 2017;17:280.
    >> Share

  43. CHAN S, Chen JH, Li S, Chang R, et al
    Evaluation of the association between quantitative mammographic density and breast cancer occurred in different quadrants.
    BMC Cancer. 2017;17:274.
    >> Share

  44. PESTALOZZI BC, Tausch C, Dedes KJ, Rochlitz C, et al
    Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
    BMC Cancer. 2017;17:265.
    >> Share

  45. VAN DEN BERG MM, Winkels RM, de Kruif JT, van Laarhoven HW, et al
    Weight change during chemotherapy in breast cancer patients: a meta-analysis.
    BMC Cancer. 2017;17:259.
    >> Share

  46. SPITZWIESER M, Entfellner E, Werner B, Pulverer W, et al
    Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    BMC Cancer. 2017;17:260.
    >> Share

  47. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    >> Share

  48. JOVANOVIC B, Sheng Q, Seitz RS, Lawrence KD, et al
    Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
    BMC Cancer. 2017;17:241.
    >> Share

  49. MELVIN JC, Garmo H, Holmberg L, Hammar N, et al
    Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
    BMC Cancer. 2017;17:246.
    >> Share

    March 2017
  50. ARIAANS G, Jalving M, Vries EG, Jong S, et al
    Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
    BMC Cancer. 2017;17:232.
    >> Share

  51. KURBEL S, Dmitrovic B, Marjanovic K, Vrbanec D, et al
    Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology.
    BMC Cancer. 2017;17:231.
    >> Share

  52. OBERGUGGENBERGER A, Meraner V, Sztankay M, Beer B, et al
    Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
    BMC Cancer. 2017;17:226.
    >> Share

  53. GARCIA-SAENZ JA, Ayllon P, Laig M, Acosta-Eyzaguirre D, et al
    Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
    BMC Cancer. 2017;17:210.
    >> Share

  54. PETERS IT, van der Steen MA, Huisman BW, Hilders CG, et al
    Morphological and phenotypical features of ovarian metastases in breast cancer patients.
    BMC Cancer. 2017;17:206.
    >> Share

  55. PADRO M, Louie RJ, Lananna BV, Krieg AJ, et al
    Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2017;17:203.
    >> Share

  56. LIM JP, Shyamasundar S, Gunaratne J, Scully OJ, et al
    YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.
    BMC Cancer. 2017;17:201.
    >> Share

  57. DODOVA RI, Mitkova AV, Dacheva DR, Hadjo LB, et al
    Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    BMC Cancer. 2017;17:195.
    >> Share

  58. HUANG Y, Burns DJ, Rich BE, MacNeil IA, et al
    Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
    BMC Cancer. 2017;17:199.
    >> Share

  59. DOS SANTOS AF, Terra LF, Wailemann RA, Oliveira TC, et al
    Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.
    BMC Cancer. 2017;17:194.
    >> Share

  60. CHARAGHVANDI RK, van Asselen B, Philippens ME, Verkooijen HM, et al
    Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.
    BMC Cancer. 2017;17:181.
    >> Share

  61. KROZ M, Reif M, Glinz A, Berger B, et al
    Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design.
    BMC Cancer. 2017;17:166.
    >> Share

    February 2017
  62. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    BMC Cancer. 2017;17:160.
    >> Share

  63. MORRIS M, Woods LM, Bhaskaran K, Rachet B, et al
    Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening progr
    BMC Cancer. 2017;17:155.
    >> Share

  64. MCKINNON CM, Mellor H
    The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B.
    BMC Cancer. 2017;17:145.
    >> Share

  65. SINN HP, Schneeweiss A, Keller M, Schlombs K, et al
    Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    BMC Cancer. 2017;17:124.
    >> Share

  66. EFFI AB, Aman NA, Koui BS, Koffi KD, et al
    Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    BMC Cancer. 2017;17:115.
    >> Share

  67. JAISWAL R, Johnson MS, Pokharel D, Krishnan SR, et al
    Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion.
    BMC Cancer. 2017;17:104.
    >> Share

  68. WENGSTROM Y, Bolam KA, Mijwel S, Sundberg CJ, et al
    Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy.
    BMC Cancer. 2017;17:100.
    >> Share

  69. BARBA M, Vici P, Pizzuti L, Di Lauro L, et al
    Body mass index modifies the relationship between gamma-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
    BMC Cancer. 2017;17:101.
    >> Share

    January 2017
  70. LAVENDER N, Yang J, Chen SC, Sai J, et al
    The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.
    BMC Cancer. 2017;17:88.
    >> Share

  71. VIERKANT RA, Degnim AC, Radisky DC, Visscher DW, et al
    Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.
    BMC Cancer. 2017;17:84.
    >> Share

  72. ROININEN N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, et al
    Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study.
    BMC Cancer. 2017;17:72.
    >> Share

  73. AUGUSTIN LS, Libra M, Crispo A, Grimaldi M, et al
    Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial.
    BMC Cancer. 2017;17:69.
    >> Share

  74. VESUNA F, Bergman Y, Raman V
    Genomic pathways modulated by Twist in breast cancer.
    BMC Cancer. 2017;17:52.
    >> Share

  75. NANDI P, Girish GV, Majumder M, Xin X, et al
    PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
    BMC Cancer. 2017;17:11.
    >> Share

  76. SORENSEN KM, Meldgaard T, Melchjorsen CJ, Fridriksdottir AJ, et al
    Upregulation of Mrps18a in breast cancer identified by selecting phage antibody libraries on breast tissue sections.
    BMC Cancer. 2017;17:19.
    >> Share

  77. SHACHAR SS, Mashiach T, Fried G, Drumea K, et al
    Biopsy of breast cancer metastases: patient characteristics and survival.
    BMC Cancer. 2017;17:7.
    >> Share

    December 2016
  78. SCHULER-TOPRAK S, Haring J, Inwald EC, Moehle C, et al
    Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro.
    BMC Cancer. 2016;16:951.
    >> Share

  79. GIBBONS A, Groarke A, Sweeney K
    Predicting general and cancer-related distress in women with newly diagnosed breast cancer.
    BMC Cancer. 2016;16:935.
    >> Share

  80. LIN FP, Pokorny A, Teng C, Dear R, et al
    Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach.
    BMC Cancer. 2016;16:929.
    >> Share

    November 2016
  81. HONG R, Ma F, Zhang W, Yu X, et al
    Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:925.
    >> Share

  82. ARPINO G, Pensabene M, Condello C, Ruocco R, et al
    Tumor characteristics and prognosis in familial breast cancer.
    BMC Cancer. 2016;16:924.
    >> Share

  83. VANKLOMPENBERG MK, Bedalov CO, Soto KF, Prosperi JR, et al
    Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancer.
    BMC Cancer. 2016;16:921.
    >> Share

  84. ATEMA V, van Leeuwen M, Oldenburg HS, Retel V, et al
    Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.
    BMC Cancer. 2016;16:920.
    >> Share

  85. KOSALOGLU Z, Bitzer J, Halama N, Huang Z, et al
    In silico SNP analysis of the breast cancer antigen NY-BR-1.
    BMC Cancer. 2016;16:901.
    >> Share

  86. MAGNUSSON K, Gremel G, Ryden L, Ponten V, et al
    ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
    BMC Cancer. 2016;16:904.
    >> Share

  87. WANG Y, Chen L, Wu Z, Wang M, et al
    miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL.
    BMC Cancer. 2016;16:826.
    >> Share

  88. CHEN J, Shin VY, Siu MT, Ho JC, et al
    miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    BMC Cancer. 2016;16:887.
    >> Share

  89. GEIGER P, Mayer B, Wiest I, Schulze S, et al
    Binding of galectin-1 to breast cancer cells MCF7 induces apoptosis and inhibition of proliferation in vitro in a 2D- and 3D- cell culture model.
    BMC Cancer. 2016;16:870.
    >> Share

  90. MONROY-CISNEROS K, Esparza-Romero J, Valencia ME, Guevara-Torres AG, et al
    Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
    BMC Cancer. 2016;16:860.
    >> Share

  91. BLODT S, Mittring N, Schutzler L, Fischer F, et al
    A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study.
    BMC Cancer. 2016;16:843.
    >> Share

  92. WINSLOW S, Lindquist KE, Edsjo A, Larsson C, et al
    The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
    BMC Cancer. 2016;16:841.
    >> Share

  93. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    >> Share

  94. MASARWAH A, Auvinen P, Sudah M, Dabravolskaite V, et al
    Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
    BMC Cancer. 2016;16:833.
    >> Share

    October 2016
  95. REEVES MM, Terranova CO, Erickson JM, Job JR, et al
    Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer.
    BMC Cancer. 2016;16:830.
    >> Share

  96. WOLF B, Goebel G, Hackl H, Fiegl H, et al
    Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    BMC Cancer. 2016;16:821.
    >> Share

  97. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2016;16:819.
    >> Share

  98. MIAO H, Hartman M, Verkooijen HM, Taib NA, et al
    Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia.
    BMC Cancer. 2016;16:820.
    >> Share

  99. ZHOU Y, Lin S, Tseng KF, Han K, et al
    Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:818.
    >> Share

  100. BECKER MA, Hou X, Tienchaianada P, Haines BB, et al
    Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    BMC Cancer. 2016;16:814.
    >> Share

  101. YU Y, Cui N, Li HY, Wu YM, et al
    Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine n
    BMC Cancer. 2016;16:808.
    >> Share

  102. NEKULOVA M, Holcakova J, Gu X, Hrabal V, et al
    DeltaNp63alpha expression induces loss of cell adhesion in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:782.
    >> Share

  103. ROCHLITZ C, Bigler M, von Moos R, Bernhard J, et al
    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase II
    BMC Cancer. 2016;16:780.
    >> Share

    February 2016
  104. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    >> Share

  105. NOLAN RM, Adie SG, Marjanovic M, Chaney EJ, et al
    Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer.
    BMC Cancer. 2016;16:144.
    >> Share

    January 2016
  106. DIESSNER J, Wischnewsky M, Stuber T, Stein R, et al
    Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    BMC Cancer. 2016;16:307.
    >> Share

  107. HENDERSON SL, Teft WA, Kim RB
    Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFalpha biologic for ulcerative colitis: a case report.
    BMC Cancer. 2016;16:304.
    >> Share

  108. SOMASUNDARAM V, Hemalatha SK, Pal K, Sinha S, et al
    Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    BMC Cancer. 2016;16:336.
    >> Share

  109. MOSLEHI R, Freedman E, Zeinomar N, Veneroso C, et al
    Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.
    BMC Cancer. 2016;16:334.
    >> Share

  110. BAZZI ZA, Lanoue D, El-Youssef M, Romagnuolo R, et al
    Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    BMC Cancer. 2016;16:328.
    >> Share

  111. CLARE SE, Gupta A, Choi M, Ranjan M, et al
    Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes.
    BMC Cancer. 2016;16:326.
    >> Share

  112. CHEN Y, Chen K, Xiao X, Nie Y, et al
    Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:320.
    >> Share

  113. KIM HA, Ahn SH, Nam SJ, Park S, et al
    The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
    BMC Cancer. 2016;16:319.
    >> Share

  114. ARROSPIDE A, Rue M, van Ravesteyn NT, Comas M, et al
    Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    BMC Cancer. 2016;16:344.
    >> Share

  115. GANGADHARA S, Smith C, Barrett-Lee P, Hiscox S, et al
    3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
    BMC Cancer. 2016;16:345.
    >> Share

  116. CAO Y, Feng Y, Zhang Y, Zhu X, et al
    L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.
    BMC Cancer. 2016;16:343.
    >> Share

  117. REIMER T, Kempert S, Gerber B, Thiesen HJ, et al
    SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.
    BMC Cancer. 2016;16:337.
    >> Share

  118. GOLUBNITSCHAJA O, Yeghiazaryan K, Stricker H, Trog D, et al
    Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours.
    BMC Cancer. 2016;16:357.
    >> Share

  119. MAGHOUS A, Rais F, Ahid S, Benhmidou N, et al
    Factors influencing diagnosis delay of advanced breast cancer in Moroccan women.
    BMC Cancer. 2016;16:356.
    >> Share

  120. MILLER K, Cortes J, Hurvitz SA, Krop IE, et al
    HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer.
    BMC Cancer. 2016;16:352.
    >> Share

  121. BOUCHARD G, Therriault H, Geha S, Berube-Lauziere Y, et al
    Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
    BMC Cancer. 2016;16:361.
    >> Share

  122. JANSSON S, Bendahl PO, Larsson AM, Aaltonen KE, et al
    Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    BMC Cancer. 2016;16:433.
    >> Share

  123. LAIBLE M, Schlombs K, Kaiser K, Veltrup E, et al
    Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    BMC Cancer. 2016;16:398.
    >> Share

  124. DAVIES EA, Coupland VH, Dixon S, Mokbel K, et al
    Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses.
    BMC Cancer. 2016;16:421.
    >> Share

  125. KOBAYASHI T, Tomomatsu J, Fukada I, Shibayama T, et al
    Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:404.
    >> Share

  126. LEE ES, Han W, Kim MK, Kim J, et al
    Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
    BMC Cancer. 2016;16:430.
    >> Share

  127. JUECKSTOCK J, Rack B, Friedl TW, Scholz C, et al
    Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    BMC Cancer. 2016;16:401.
    >> Share

  128. WINKEL RR, von Euler-Chelpin M, Nielsen M, Petersen K, et al
    Mammographic density and structural features can individually and jointly contribute to breast cancer risk assessment in mammography screening: a case-control study.
    BMC Cancer. 2016;16:414.
    >> Share

  129. YANG M, Ma B, Shao H, Clark AM, et al
    Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
    BMC Cancer. 2016;16:419.
    >> Share

  130. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum HER2 extra-cellular domain, S100ss and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    BMC Cancer. 2016;16:428.
    >> Share

  131. KANGASPESKA S, Hultsch S, Jaiswal A, Edgren H, et al
    Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
    BMC Cancer. 2016;16:378.
    >> Share

  132. GARGIULO P, Pensabene M, Milano M, Arpino G, et al
    Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    BMC Cancer. 2016;16:375.
    >> Share

  133. FLORES-PEREZ A, Marchat LA, Rodriguez-Cuevas S, Bautista VP, et al
    Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.
    BMC Cancer. 2016;16:379.
    >> Share

  134. YU X, Hu G, Zhang Z, Qiu F, et al
    Retrospective and comparative analysis of (99m)Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women.
    BMC Cancer. 2016;16:450.
    >> Share

  135. ZDUNIAK K, Agrawal A, Agrawal S, Hossain MM, et al
    Osteopontin splice variants are differential predictors of breast cancer treatment responses.
    BMC Cancer. 2016;16:441.
    >> Share

  136. DENG W, Wang Y, Gu L, Duan B, et al
    MICAL1 controls cell invasive phenotype via regulating oxidative stress in breast cancer cells.
    BMC Cancer. 2016;16:489.
    >> Share

  137. MARTINEZ JA, Chalasani P, Thomson CA, Roe D, et al
    Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    BMC Cancer. 2016;16:500.
    >> Share

  138. LUI A, New J, Ogony J, Thomas S, et al
    Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    BMC Cancer. 2016;16:487.
    >> Share

  139. COURNEYA KS, McNeely ML, Culos-Reed SN, Vallance JK, et al
    The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants.
    BMC Cancer. 2016;16:481.
    >> Share

  140. CHEN BB, Lu YS, Lin CH, Chen WW, et al
    A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    BMC Cancer. 2016;16:466.
    >> Share

  141. STEIN RG, Wollschlager D, Kreienberg R, Janni W, et al
    The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients.
    BMC Cancer. 2016;16:459.
    >> Share

  142. COCKBURN JG, Hallett RM, Gillgrass AE, Dias KN, et al
    The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
    BMC Cancer. 2016;16:555.
    >> Share

  143. AL-HOWAIL HA, Hakami HA, Al-Otaibi B, Al-Mazrou A, et al
    PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    BMC Cancer. 2016;16:540.
    >> Share

  144. VILSMAIER T, Rack B, Janni W, Jeschke U, et al
    Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.
    BMC Cancer. 2016;16:547.
    >> Share

  145. BAUMANN J, Wong J, Sun Y, Conklin DS, et al
    Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    BMC Cancer. 2016;16:551.
    >> Share

  146. WU LA, Kuo WH, Chen CY, Tsai YS, et al
    The association of infrared imaging findings of the breast with prognosis in breast cancer patients: an observational cohort study.
    BMC Cancer. 2016;16:541.
    >> Share

  147. ZHU J, Zhuang T, Yang H, Li X, et al
    Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression.
    BMC Cancer. 2016;16:538.
    >> Share

  148. AKTAS B, Kasimir-Bauer S, Muller V, Janni W, et al
    Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    BMC Cancer. 2016;16:522.
    >> Share

  149. ZHANG S, Li L, Wang T, Bian L, et al
    Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    BMC Cancer. 2016;16:526.
    >> Share

  150. PLOOS VAN AMSTEL FK, Prins JB, van der Graaf WT, Peters ME, et al
    The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial.
    BMC Cancer. 2016;16:520.
    >> Share

  151. VAN HELMONDT SJ, van der Lee ML, de Vries J
    Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer.
    BMC Cancer. 2016;16:527.
    >> Share

  152. BLOOMQUIST K, Hayes S, Adamsen L, Moller T, et al
    A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol.
    BMC Cancer. 2016;16:517.
    >> Share

  153. YANG Y, Im SA, Keam B, Lee KH, et al
    Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
    BMC Cancer. 2016;16:515.
    >> Share

  154. BERNAL-ESTEVEZ D, Sanchez R, Tejada RE, Parra-Lopez C, et al
    Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
    BMC Cancer. 2016;16:591.
    >> Share

  155. CHOI SK, Kim HS, Jin T, Hwang EH, et al
    Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    BMC Cancer. 2016;16:570.
    >> Share

  156. SHE QB, Gruvberger-Saal SK, Maurer M, Chen Y, et al
    Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    BMC Cancer. 2016;16:587.
    >> Share

  157. MARTINEZ L, Thames E, Kim J, Chaudhuri G, et al
    Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis.
    BMC Cancer. 2016;16:559.
    >> Share

  158. KUHLMANN JD, Bankfalvi A, Schmid KW, Callies R, et al
    Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
    BMC Cancer. 2016;16:618.
    >> Share

  159. HUBER MC, Mall R, Braselmann H, Feuchtinger A, et al
    uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    BMC Cancer. 2016;16:615.
    >> Share

  160. JIN X, Jiang YZ, Chen S, Yu KD, et al
    A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
    BMC Cancer. 2016;16:606.
    >> Share

  161. MC MENAMIN UC, Murray LJ, Hughes CM, Cardwell CR, et al
    Statin use and breast cancer survival: a nationwide cohort study in Scotland.
    BMC Cancer. 2016;16:600.
    >> Share

  162. MCNEELY ML, Campbell KL, Webster M, Kuusk U, et al
    Efficacy of night-time compression for breast cancer related lymphedema (LYNC): protocol for a multi-centre, randomized controlled efficacy trial.
    BMC Cancer. 2016;16:601.
    >> Share

  163. REZANIA S, Kammerer S, Li C, Steinecker-Frohnwieser B, et al
    Overexpression of KCNJ3 gene splice variants affects vital parameters of the malignant breast cancer cell line MCF-7 in an opposing manner.
    BMC Cancer. 2016;16:628.
    >> Share

  164. RUDOLPH M, Anzeneder T, Schulz A, Beckmann G, et al
    AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    BMC Cancer. 2016;16:622.
    >> Share

  165. RASHID MU, Muhammad N, Bajwa S, Faisal S, et al
    High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    BMC Cancer. 2016;16:673.
    >> Share

  166. KRSTIC M, Macmillan CD, Leong HS, Clifford AG, et al
    The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
    BMC Cancer. 2016;16:671.
    >> Share

  167. TAKAHASHI Y, Uruga H, Fujii T, Mochizuki S, et al
    Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report.
    BMC Cancer. 2016;16:666.
    >> Share

  168. DIERSSEN-SOTOS T, Gomez-Acebo I, de Pedro M, Perez-Gomez B, et al
    Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.
    BMC Cancer. 2016;16:660.
    >> Share

  169. GUERRA E, Cimadamore A, Simeone P, Vacca G, et al
    p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.
    BMC Cancer. 2016;16:649.
    >> Share

  170. PROSKURINA AS, Gvozdeva TS, Potter EA, Dolgova EV, et al
    Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
    BMC Cancer. 2016;16:651.
    >> Share

  171. GREGOIRE JM, Fleury L, Salazar-Cardozo C, Alby F, et al
    Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells.
    BMC Cancer. 2016;16:700.
    >> Share

  172. CHEN CY, Yang CY, Chen YC, Shih CW, et al
    Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
    BMC Cancer. 2016;16:697.
    >> Share

  173. ZHOU K, Wang D, He X, Huo L, et al
    Effectiveness of a multimodal standard nursing program on health-related quality of life in Chinese mainland female patients with breast cancer: protocol for a single-blind cluster randomized controlled trial.
    BMC Cancer. 2016;16:698.
    >> Share

  174. SHOU J, Zhang Z, Lai Y, Chen Z, et al
    Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
    BMC Cancer. 2016;16:687.
    >> Share

  175. MENESES-ECHAVEZ JF, Jimenez EG, Rio-Valle JS, Correa-Bautista JE, et al
    The insulin-like growth factor system is modulated by exercise in breast cancer survivors: a systematic review and meta-analysis.
    BMC Cancer. 2016;16:682.
    >> Share

  176. KUBECEK O, Soukup T, Paulik A, Kopecky J, et al
    Dermatomyositis with anti-TIF-1gamma antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    BMC Cancer. 2016;16:684.
    >> Share

  177. MIN L, Zhang C, Ma R, Li X, et al
    Overexpression of synuclein-gamma predicts lack of benefit from radiotherapy for breast cancer patients.
    BMC Cancer. 2016;16:717.
    >> Share

  178. HENNIGS A, Riedel F, Gondos A, Sinn P, et al
    Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.
    BMC Cancer. 2016;16:734.
    >> Share

  179. ROMERO A, Tora-Rocamora I, Bare M, Barata T, et al
    Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs.
    BMC Cancer. 2016;16:735.
    >> Share

  180. HONG R, Ma F, Zhang W, Yu X, et al
    53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:725.
    >> Share

  181. OH K, Lee OY, Park Y, Seo MW, et al
    IL-1beta induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
    BMC Cancer. 2016;16:724.
    >> Share

  182. CORDINA-DUVERGER E, Truong T, Anger A, Sanchez M, et al
    Weight and weight changes throughout life and postmenopausal breast cancer risk: a case-control study in France.
    BMC Cancer. 2016;16:761.
    >> Share

  183. HADAD SM, Jordan LB, Roy PG, Purdie CA, et al
    A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
    BMC Cancer. 2016;16:745.
    >> Share

  184. MATSUMURA K, Nakata S, Taniguchi K, Ii H, et al
    Depletion of gamma-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
    BMC Cancer. 2016;16:748.
    >> Share

    January 2015
  185. FRAMARINO-DEI-MALATESTA M, Perrone G, Giancotti A, Ventriglia F, et al
    Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.
    BMC Cancer. 2015;15:951.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016